velpatasvir and voxilaprevir
GPTKB entity
Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug_combination
|
| gptkbp:approvalYear |
2017
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:component |
gptkb:voxilaprevir
velpatasvir |
| gptkbp:contains |
gptkb:sofosbuvir
|
| gptkbp:indication |
chronic hepatitis C infection
|
| gptkbp:marketedAs |
gptkb:Vosevi
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:usedFor |
treatment of hepatitis C
|
| gptkbp:bfsParent |
gptkb:sofosbuvir
|
| gptkbp:bfsLayer |
6
|
| https://www.w3.org/2000/01/rdf-schema#label |
velpatasvir and voxilaprevir
|